Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing - Wikidata - thesis-toulmin - TriplyDB

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

http://www.wikidata.org/entity/Q28275103

about

Cancer genome landscapes mRNAs and miRNAs in whole blood associated with lung hyperplasia, fibrosis, and bronchiolo-alveolar adenoma and adenocarcinoma after multi-walled carbon nanotube inhalation exposure in mice The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes Molecular biology of lung cancer Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Epigenetic modulators, modifiers and mediators in cancer aetiology and progression Effects of Charged Particles on Human Tumor Cells Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population Mediator kinase module and human tumorigenesis Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications Predictive biomarkers in precision medicine and drug development against lung cancer Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin From human genome to cancer genome: the first decade Mutational signatures: the patterns of somatic mutations hidden in cancer genomes Endogenous retroviruses and the development of cancer Functional genomics lead to new therapies in follicular lymphoma Genomic sequencing in cancer Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics Lung cancer chemoprevention: current status and future prospects SWI/SNF chromatin remodeling complexes and cancer Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design New insights and challenges in mismatch repair: getting over the chromatin hurdle Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Emerging patterns of somatic mutations in cancer Apoptotic agents Targeted therapies in development for non-small cell lung cancer Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Diversity of epithelial stem cell types in adult lung.Structure of chromatin remodeler Swi2/Snf2 in the resting state Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.Therapeutic targeting of cancers with loss of PTEN function.Oncogenic RIT1 mutations in lung adenocarcinoma.Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors Mutant HRAS as novel target for MEK and mTOR inhibitors Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.

P2860

Q22242276-6959FCA2-14EB-4617-A6D3-2BD0E7C055D6 Q23910476-7B3A8F20-24AA-494D-890E-2E7B19167466 Q24339204-2164567F-1AB7-4362-BAFD-533731E8BA30 Q24596715-4193F999-60A9-4615-9392-A7D311883A29 Q24606677-8845B1E2-80DD-4840-82FF-78BF13C2FE62 Q26741318-C3223E6B-0844-4B81-9691-8A8B638A199A Q26766149-0FC97CD8-4AAC-44A3-A37E-A66A547E99F5 Q26767252-D010A835-A521-4B9A-B7A4-9812EB874576 Q26769744-86BC8590-CE66-4E95-BAD9-95F1F1690343 Q26773479-EE8FAC53-77DE-4F68-A407-FA25AAB66A81 Q26786594-20ED699E-AB5E-4808-BACA-232BAB06A0A1 Q26800203-1C976EF9-6039-4A99-9C3D-85091B08FF37 Q26801718-10B41902-DB46-4713-A171-75CCF675A750 Q26824536-A2654AE0-F02F-494D-B90A-BFA69AEDD02F Q26826437-1039AFEE-C920-4580-8538-4E0748DDE361 Q26827640-C90C1710-69C3-40DD-BF67-367CDAB651EB Q26850125-C8917B02-41AB-416A-98CD-6E5EC5B88C12 Q26852000-9EA952D9-50EC-4CC2-BB44-E592FB1E76DE Q26852415-38F467C2-B8B1-49F1-897F-5A496C260A64 Q26853507-E9D54CD2-B742-4574-8A9B-65C0B10AE1FE Q26864332-C104E1C7-4348-4D1A-9E5A-50AC73671E1C Q26995495-5DD0AA7E-0274-4241-AF88-E73B5045311C Q26998657-AD056D7F-BC2D-4739-B387-54FD943AC52D Q27003440-667B8412-6DFB-4845-A4F1-6ACCFEF8AF36 Q27011117-22080FE2-3649-435F-8667-077540B3A8FB Q27014117-460387DD-4D38-468B-AC16-553B815956F0 Q27014126-8B750EE8-A614-413C-9D0F-2B0CC349C5D8 Q27016160-28275352-73F3-4F8C-AE12-4EE5909A1FE1 Q27022852-4E6E7094-81FF-45A3-A47A-5582BAC15CCB Q27345462-93283E4A-7F43-4CAB-9065-07362140A8C8 Q27687294-F2E612A1-1D5E-4DA2-A2CB-74846BAAB4B9 Q27718346-CBC6C422-0DA4-43DD-A937-EF2F670FDA53 Q27852128-58219732-7DB2-4D50-8ECB-EAAC5D219C99 Q27852764-0C421847-4341-4F6B-9DAF-0D9473477A35 Q27852800-A204809A-5BA8-426E-9FF8-92FFED92F2F3 Q27852873-B61B17F9-6289-42BB-B8F1-57B5EC0DC801 Q27853005-BEEFA333-EADA-4CE7-8B0D-DE55D65C4602 Q27853211-F32747F2-6778-49A7-9C29-E7C566888D60 Q27853238-75854DA8-9273-475C-B9F1-5FFF8BFE0B7B Q27853286-7522C759-96D0-40F7-92A4-60EFCDF38EFB

P2860

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

http://www.wikidata.org/entity/Q28275103

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@ast

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@en

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@nl

type

label

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@ast

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@en

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@nl

prefLabel

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@ast

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@en

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@nl

P1433

Q28275103-2279301D-6738-4358-969C-A3109FB08600

P1476

Q28275103-711F105F-50C0-452E-9384-90A4A5688399

P2093

Q28275103-0A23ABC9-9741-4EED-A146-21E3F3F06B6A

Q28275103-1343A83D-7EA2-40C8-A10E-A7AFDF6A5853

Q28275103-30465FBD-9ED0-4E3C-9918-B2DBD3063DF9

Q28275103-502BC3B6-1EA3-4403-A890-108D2A70EDD1

Q28275103-52C92064-F08E-48C1-AA59-B34FF27FD94B

Q28275103-536FAF7F-A484-486F-A518-3ABF24ED565C

Q28275103-5C1E1A24-7913-4E80-BE23-E2F894494B1A

Q28275103-751809C3-55CE-41BC-A2CE-D01F1FE0B42D

Q28275103-7A67C68D-57F8-431C-B6A2-761023224EB2

Q28275103-859682FB-6CCD-4780-BB6A-59071141624A

P2860

Q28275103-00B30047-6B37-4645-9654-3D544FF05140

Q28275103-01299318-EE1D-4ACD-BFC8-3C956FBB7B71

Q28275103-015F244B-97BE-4154-A539-41C3545D747F

Q28275103-108944D1-8ABE-4CCE-AC77-970699BD0000

Q28275103-12270E0C-911C-473E-B527-17F507B10772

Q28275103-128D68FE-1EDC-4AE0-AAE0-AED319FF8FB6

Q28275103-158AB0CE-4467-49DB-9A0E-CB451EC896E6

Q28275103-1CB5432F-30B0-4F0C-8548-C7A4A1CB347B

Q28275103-1D1AF7D9-828F-45D1-997F-B109C00B5023

Q28275103-25FC9C2D-EAB3-483D-82D3-6270EF45B1AD

P304

Q28275103-4B239797-AA10-4332-9960-A7CB23B79C4B

P31

Q28275103-D00020B2-003D-41D0-8FF2-8CF7767156A7

P3181

Q28275103-AA7E40FE-BD80-468A-82ED-CADEE08B59FA

P356

Q28275103-2709BCB6-4C6D-4BB9-A1DF-3B60DAE998F9

P407

Q28275103-396A8D3A-4303-4E29-83C4-586869D39EA8

P433

Q28275103-A8130BE3-AC95-4951-ADB0-CD52878D5B1B

P478

Q28275103-99D7969A-E4EE-4CB2-B2D0-F9FA77CD7A89

P50

Q28275103-00909502-B631-495E-9C95-27C94CC7E678

Q28275103-0E36BC1B-E716-44BE-961E-36F98653DDEB

Q28275103-17F57468-CD7D-431B-B1E5-943A77513CA5

Q28275103-25C9BE58-DD57-4A31-8CFC-DB61838B22DB

Q28275103-42B0C59D-0FA1-4962-82C6-3E24FD35D4CF

Q28275103-4906874F-8ADD-472D-B7E3-8C8AC95D2107

Q28275103-700289B8-F259-4549-BFDB-FF9DC9684EC0

Q28275103-7045FD27-CA18-4DD7-B2C3-BA020F69589C

Q28275103-9B0BCEA1-8EF7-4E81-AC12-59E8195BD658

Q28275103-B6C1AF7A-5B5C-4A22-A734-CD8174E5F578

P577

Q28275103-ED2893A5-9A03-40C2-8D33-51DCDDF5D83B

P5875

Q28275103-B77331C9-1642-4FFC-AAEB-10C5445BCEC6

P698

Q28275103-BBCE185D-75CC-4FF9-B2F2-D48EA2DCAE1E

P921

Q28275103-F954E136-10A2-43F3-ADAE-BC4430138E38

P932

Q28275103-7C1253B7-73FA-441F-BF5D-0648CBA729E4

P3181

P356

J.CELL.2012.08.029

P1433

P1476

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

@en

P2093

Alice H Berger

http://www.w3.org/2001/XMLSchema#string

Andrey Sivachenko

http://www.w3.org/2001/XMLSchema#string

Angela Brooks

http://www.w3.org/2001/XMLSchema#string

Bruce E Johnson

http://www.w3.org/2001/XMLSchema#string

Bryan Hernandez

http://www.w3.org/2001/XMLSchema#string

Chandra Goparju

http://www.w3.org/2001/XMLSchema#string

Corinna Ludwig

http://www.w3.org/2001/XMLSchema#string

David Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Erich Stoelben

http://www.w3.org/2001/XMLSchema#string

Frauke Leenders

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

The Hallmarks of Cancer

Hallmarks of Cancer: The Next Generation

Importance of autophosphorylation at Ser186 in the A-loop of salt inducible kinase 1 for its sustained kinase activity

Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

A landscape of driver mutations in melanoma

Melanoma genome sequencing reveals frequent PREX2 mutations

The genomic complexity of primary human prostate cancer

Initial genome sequencing and analysis of multiple myeloma

P304

1107-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

901974

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CELL.2012.08.029

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

150

http://www.w3.org/2001/XMLSchema#string

P50

Kristian Cibulskis

Marcin Imielinski

P577

2012-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230861583

http://www.w3.org/2001/XMLSchema#string

P698

22980975

http://www.w3.org/2001/XMLSchema#string

P921

P932

3557932

http://www.w3.org/2001/XMLSchema#string